The Long Non-Coding RNA SBF2-AS1 Exerts Oncogenic Functions In Gastric Cancer By Targeting The miR-302b-3p/E2F Transcription Factor 3 Axis (Retracted Article)
The Long Non-Coding RNA SBF2-AS1 Exerts Oncogenic Functions In Gastric Cancer By Targeting The miR-302b-3p/E2F Transcription Factor 3 Axis (Retracted Article)
复制标题
DOI：
10.2147/ott.s210697
复制
发表时间：
2019-01-01
影响因子：
4
通讯作者：
Guo, Jiansheng
中科院分区：
文献类型：
--
作者：
Liang, Chaojie;Yue, Chaosen;Guo, Jiansheng
背景与目的：研究表明，长非编码RNA SBF2-AS1在肿瘤进展中起关键作用，但SBF2-AS1在胃癌中的作用尚未见报道。因此，本研究旨在阐明SBF2-AS1在胃癌中的作用机制。方法：基于基因表达数据库和TCGA数据库的Meta分析，探讨SBF2-AS1在胃癌中的预后价值。采用RT-PCR方法检测SBF2-AS1在胃癌中的临床病理意义。结果：SBF2-AS1在胃癌组织和细胞系中过表达，SBF2-AS1过表达提示总体生存率较低，可作为独立的预后因素。此外，SBF2-AS1基因的敲除抑制了细胞的生长、侵袭和转移，促进了细胞的凋亡，并导致细胞周期停滞。荧光素酶报告和得失功能分析表明，SBF2-AS1是microRNA(MiR)-302B-3p的竞争内源(Cerna)，阻断了miR-302B-3p对E2F转录因子3(E2F3)的抑制作用。结论：SBF2-AS1可能是一种潜在的胃癌诊断和预后生物标志物，SBF2-AS1可能通过miR-302B-3p/E2F3轴促进肿瘤进展。
Background and aims: Studies show that the long non-coding RNA, SBF2-AS1, plays a critical role in cancer progression, but the role of SBF2-AS1 in gastric cancer has not been reported. Therefore, this study aimed to elucidate the mechanism of SBF2-AS1 in gastric cancer (GC).Methods: A meta-analysis, based on the gene expression omnibus database and TCGA dataset was performed to explore the prognostic value of SBF2-AS1 in GC. RT-PCR was also conducted to investigate the clinicopathologic value of SBF2-AS1 in GC. The effect of SBF2-AS1 in GC cell lines was conducted by gain or loss-of-function assays, and the SBF2-AS1 target gene was confirmed using a luciferase reporter assay and bioinformatics.Results: SBF2-AS1 was overexpressed in GC tissues and cell lines, and SBF2-AS1 overexpression indicated poor overall survival and could serve as an independent prognostic factor. Moreover, knockdown of SBF2-AS1 inhibited cell growth, invasion, and metastasis, promoted apoptosis, and caused cell cycle arrest. Luciferase reporter and gain- or loss-offunction assays indicated that SBF2-AS1 acted as a competing endogenous (ceRNA) for microRNA (miR)-302b-3p, which blocked the inhibitory effect of miR-302b-3p on the E2F transcription factor 3 (E2F3).Conclusion: SBF2-AS1 could be a potential diagnostic and prognostic biomarker in GC, and SBF2-AS1 accelerates tumor progression via the miR-302b-3p/E2F3 axis.